Unlocking New Horizons in Childhood Leukemia Treatment with Rapamycin and Dexamethasone
In an exciting breakthrough for childhood cancer treatment, researchers have combined two drugs, dexamethasone and rapamycin, showing significant advancements in combating Acute Lymphoblastic Leukemia (ALL). This innovative combination targets drug-resistant pathways in leukemia cells, utilizing the power of two distinct approaches to enhance treatment efficacy. The research specifically underscores the benefits of overcoming bone marrow stroma-mediated resistance, paving the way for more resilient and effective therapeutic strategies.
Feb 17